News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Immunotech Laboratories in Discussions for Pre-"IND" Testing of Aids-HIV "IPF" Treatment in the USA



3/18/2013 9:29:40 AM

MONROVIA, CA--(Marketwire - March 18, 2013) - Immunotech Laboratories, Inc. (PINKSHEETS: IMMB) today announced the company has begun discussions with a professional medical consulting group to start the process for Pre-IND (Investigational New Drug) application in the USA.

This application could pave the way for Immunotech's patented "IPF" Treatment to be submitted to the Food & Drug Administration (FDA) for approval.

Information about the Pre-IND Purpose at:
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/Overview/ucm077546.htm

Link to Investigational New Drug Application after Pre-Clinical Testing: (Example)
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85055671

About Immunotech Laboratories
Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases such as HIV and Aids. www.immunotechlab.com

Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.


Company Contact:
Email Contact

Public Relations:
The Nabors Group:
713-875-9200
E-mail: Email Contact
www.facebook.com/Naborsgroup

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:


Read at BioSpace.com


comments powered by Disqus
   
HIV/AIDS

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES